PreCyte SSI
Prediction of surgical site infections and postoperative complications
CommercialActive
Key Facts
Indication
Prediction of surgical site infections and postoperative complications
Phase
Commercial
Status
Active
Company
About Surge
SurgeCare is a San Francisco-based biotech company founded in 2020, developing an AI-powered platform for immune biomarker discovery. Its core technology, Stabl, is a multiomics and machine learning algorithm designed to extract robust biological 'fingerprints' from complex datasets to predict clinical outcomes. The company's first commercial product line, PreCyte, focuses on predicting surgical complications, with an initial launch in the United States. Surge is backed by a team with strong academic pedigrees and has secured partnerships and investment from notable European and U.S. entities.
View full company profile